Rare Diseases Today—May 7, 2026

This week’s Rare Diseases update highlights regulatory actions, gene therapy progress, launch activity, access infrastructure, and pipeline expansion.

In Today’s Newsletter

Dive deeper

🧬 Sangrail launches with MPS IIIB AAV program [1] [US, EU • 05 May 2026]

https://www.businesswire.com/news/home/20260505269322/en/Sangrail-Biologics-Launches-with-Mission-of-Restoring-Lifes-Blueprint-for-Children-with-Rare-Genetic-Diseases
Context: Sangrail Biologics launched with SNG-101, an AAV9 gene therapy for mucopolysaccharidosis type IIIB.
Key point: Source reports 14 treated patients, biomarker reductions, enzyme activity normalization, cognitive stabilization or improvement, and favorable safety.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ Opus Genetics enters FDA RDEP for LCA5 [2] [US • 04 May 2026]

https://www.globenewswire.com/news-release/2026/05/04/3287178/0/en/Opus-Genetics-Announces-FDA-Acceptance-of-OPGx-LCA5-into-Rare-Disease-Evidence-Principles-RDEP-Program.html
Context: OPGx-LCA5 targets Leber congenital amaurosis type 5, an ultra-rare inherited retinal disease.
Key point: FDA accepted OPGx-LCA5 into the Rare Disease Evidence Principles program to support regulatory alignment.
Implication: May influence prescriber choice and payer reviews pending full data.

🧒 Atossa gains RPD designation for (Z)-endoxifen [3] [US • 04 May 2026]

https://www.prnewswire.com/news-releases/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-mccune-albright-syndrome-302760919.html
Context: Atossa Therapeutics is developing (Z)-endoxifen for McCune-Albright syndrome in females.
Key point: FDA granted Rare Pediatric Disease designation, which may qualify Atossa for a Priority Review Voucher upon approval.
Implication: Introduces regulatory optionality that may affect development strategy and future access planning.

🧫 Satellite Bio gains RPD designation for SB-101 [4] [US • 04 May 2026]

https://www.biospace.com/press-releases/satellite-bio-announces-fda-rare-pediatric-disease-designation-for-sb-101-for-the-treatment-of-urea-cycle-disorders-ucds
Context: SB-101 is an off-the-shelf liver therapy for severe early-onset urea cycle disorders.
Key point: FDA granted Rare Pediatric Disease designation, and Satellite Bio plans to start a Phase 1/2 trial in 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🧴 LEO Pharma buys Replay HSV gene therapy platform [5] [Denmark • 30 Apr 2026]

https://www.biospace.com/press-releases/leo-pharma-bolsters-rare-skin-disease-focus-through-acquisition-of-replay-gene-therapy-platform
Context: LEO Pharma agreed to acquire Replay, adding an HSV gene therapy platform for genetic skin diseases.
Key point: Replay’s lead preclinical program targets dystrophic epidermolysis bullosa.
Implication: Signals pipeline investment and modality expansion.

⚡ Stealth updates FORZINITY launch and mitochondrial pipeline [6] [US, UK • 30 Apr 2026]

https://www.biospace.com/press-releases/stealth-biotherapeutics-provides-commercial-launch-update-and-pipeline-progress-across-mitochondrial-disease-portfolio
Context: FORZINITY (elamipretide) is commercially available for eligible US Barth syndrome patients weighing at least 30 kg.
Key point: Stealth reported 33 patients initiated therapy, broad coverage, and ongoing work on label expansion and pipeline programs.
Implication: May expand screening, initiation, and follow-up at scale.

🚚 South Korea starts rare disease supply delivery service [7] [South Korea • 04 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31517
Context: South Korea’s Ministry of Health and Welfare launched direct delivery of medical supplies for rare disease patients.
Key point: The Soldoc-linked service verifies eligibility and supports delivery of items such as syringes, infusion sets, saline, and swabs.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Rare pediatric designations remain a key regulatory lever for rare disease developers, especially where PRV eligibility may support funding strategy.
Gene therapy activity is broadening across neurology, ophthalmology, dermatology, and metabolic disease.
Access infrastructure is becoming part of the rare disease story, from FORZINITY onboarding to Korea’s home-care supply delivery.
Ultra-rare disease programs are leaning on early FDA alignment, small-population evidence frameworks, and targeted development paths.

🎯 Catch up on the Top Rare Disease news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

FAQ

What is Sangrail Biologics developing for MPS IIIB?

Sangrail is developing SNG-101, an AAV9 gene therapy designed to introduce a functional NAGLU gene for mucopolysaccharidosis type IIIB. The source reports 14 treated patients across clinical and named-patient settings. [1]

Why does FDA RDEP acceptance matter for Opus Genetics’ OPGx-LCA5?

RDEP gives Opus Genetics a framework for early FDA collaboration on trial design and evidence generation in ultra-rare LCA5. The source links this to the company’s pivotal Phase 3 strategy. [2]

What did Atossa receive for (Z)-endoxifen in McCune-Albright syndrome?

FDA granted Rare Pediatric Disease designation for (Z)-endoxifen in females with McCune-Albright syndrome. Approval of a qualifying application may make Atossa eligible for a Priority Review Voucher. [3]

What is Satellite Bio’s SB-101?

SB-101 is an off-the-shelf liver therapy intended to restore metabolic liver function in severe early-onset urea cycle disorders. Satellite Bio plans to initiate a Phase 1/2 trial in 2026. [4]

What did LEO Pharma gain from acquiring Replay?

LEO Pharma gained Replay’s high-payload HSV gene therapy platform for rare genetic dermatology. Replay’s lead preclinical program targets dystrophic epidermolysis bullosa. [5]

What access updates did Stealth and South Korea report?

Stealth reported early FORZINITY uptake and patient support enrollment for Barth syndrome. South Korea launched a verified delivery service for rare disease medical supplies through Soldoc. [6][7]

Entities / Keywords

Sangrail Biologics, SNG-101, ABO-101, mucopolysaccharidosis type IIIB, MPS IIIB, Sanfilippo syndrome type B, NAGLU, AAV9
Opus Genetics, OPGx-LCA5, Leber congenital amaurosis type 5, LCA5, inherited retinal disease, RDEP, RMAT
Atossa Therapeutics, (Z)-endoxifen, McCune-Albright syndrome, MAS, Rare Pediatric Disease designation, Priority Review Voucher, PRV
Satellite Bio, Satellite Biosciences, SB-101, urea cycle disorders, UCDs, off-the-shelf liver therapy
LEO Pharma, Replay, HSV gene therapy, dystrophic epidermolysis bullosa, DEB, dermatology
Stealth BioTherapeutics, FORZINITY, elamipretide, Barth syndrome, BTHS, POLG-related myopathy, dry AMD, ReNEW, bevemipretide, SBT-589, Leigh syndrome
South Korea Ministry of Health and Welfare, Soldoc, rare disease medical supplies, telemedicine, National Health Insurance Service